2021 Targeted Therapies of Lung Cancer

Thank you for attending the IASLC 2021 Targeted Therapies of Lung Cancer Meeting

Registration is ongoing for 90 days at https://ttlc2021.iaslc.org/
Globe Background WCLC Slider

Thank you for attending the IASLC World Conference on Lung Cancer | Singapore

Registration ongoing for 90 days at wclc2020.iaslc.org
Read meeting coverage at iaslc.org/2020WCLCNews
Annual Report 2020

2020 Annual Report

Thank you for attending the IASLC 2021 Targeted Therapies of Lung Cancer Meeting
Thank you for attending the IASLC World Conference on Lung Cancer | Singapore
2020 Annual Report

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

In Focus

New Forum to Discuss Molecular Challenges

Molecular Challenges Video Image

When the initial molecular report suggested a ROS1 rearrangement, crizotinib was started in expectation of a typically great response. However, when the first on-treatment scan showed an increase in the size of the lung cancer it became obvious that this case was far from typical. Moderated by Dr. D. Ross Camidge, who provided a remote second opinion on the case, the patient, Mr. Bill Brand, and his primary oncologist, Dr. Ron Natale, discuss the twists and turns in the diagnosis and provide crucial insights on the nuances of understanding molecular testing, the best way to use and not abuse remote second opinions, and how you can and should rapidly adapt a plan that isn’t working. Mr. Brand, who had to join one molecularly specific patient support group, leave and then join another different one, also provides advice for patients regarding self-advocacy and handling direct communication with physicians.

Disclaimer

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

Lung Ambition Alliance

The IASLC has formed an alliance with three other founding organizations to allow scientists, specialists, advocates, and patients to break the barriers limiting progress and double 5-year survival rates of lung cancer by 2025.

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
13.357
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

Joint Event
Mar 25 - Mar 27 2021
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.